About This Page
This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.
Key points
- Canadian obesity guidance frames obesity as a chronic disease, not a personal failure; use person-first, non-stigmatising language
- Assess BMI, waist circumference, Edmonton Obesity Staging/complications, blood pressure, A1c, lipids, sleep apnea, MASLD, osteoarthritis, fertility, and mental health
- Look for secondary or medication-related contributors when weight gain is rapid, early-onset, syndromic, or associated with endocrine red flags
- Management combines behavioural, nutritional, physical activity, psychological, pharmacologic, and surgical options according to goals and complications
- Metabolic syndrome is a risk cluster — abdominal adiposity, dysglycemia, hypertension, hypertriglyceridemia, and low HDL — requiring cardiovascular risk reduction
Approach to the Presentation
Obesity and metabolic syndrome frequently appear in MCCQE1 stems as hypertension, diabetes, fatty liver disease, infertility, sleep apnea, osteoarthritis, depression, or cardiovascular risk rather than as a request for weight loss. A modern Canadian approach asks permission to discuss weight, uses person-first language, identifies drivers and complications, and sets health-centred goals. BMI is a screening tool, not the whole diagnosis; waist circumference, comorbidities, medications, mental health, trauma, sleep, food insecurity, and social determinants matter. Obesity Canada guidance supports a chronic disease model with escalation to pharmacotherapy or bariatric surgery when clinically appropriate.
Differential Diagnosis
| diagnosis | likelihood | key features | distinguishing test |
|---|---|---|---|
| Cushing Syndrome | must-not-miss | Central obesity with proximal myopathy, wide purple striae, bruising, thin skin, facial plethora, hypertension, diabetes | 1 mg overnight dexamethasone suppression or other first-line Cushing screen |
| Obesity with Cardiometabolic Complications | common | Central adiposity, hypertension, dyslipidemia, prediabetes/type 2 diabetes, MASLD, OSA, osteoarthritis, infertility | A1c/fasting glucose, lipids, BP, ALT, sleep apnea screen, waist circumference, risk staging |
| Metabolic Syndrome | common | Abdominal obesity plus dysglycemia, hypertension, high triglycerides, low HDL; elevated cardiovascular and diabetes risk | Clinical criteria using waist, BP, glucose/A1c, triglycerides, HDL |
| Hypothyroidism | common | Fatigue, cold intolerance, constipation, dry skin, bradycardia, modest weight gain rather than severe obesity | TSH and free T4 |
| Medication-induced Weight Gain | common | Antipsychotics, antidepressants, insulin, sulfonylureas, glucocorticoids, valproate, gabapentinoids, beta-blockers, some contraceptives | Medication timeline and alternatives review |
| Binge Eating Disorder / Mental Health Driver | common | Loss-of-control eating, distress, guilt, depression, trauma, ADHD, night eating; weight stigma worsens care avoidance | Validated screening and mental health assessment |
| Obstructive Sleep Apnea | common | Snoring, witnessed apneas, daytime sleepiness, resistant hypertension, morning headaches | STOP-Bang or sleep study |
| Polycystic Ovary Syndrome | less common | Oligomenorrhea, hirsutism, acne, infertility, insulin resistance | Clinical/biochemical hyperandrogenism and ovulatory dysfunction assessment |
| Genetic or Syndromic Obesity | rare | Severe early-onset obesity, hyperphagia, developmental delay, dysmorphic features, family history | Specialist genetics/endocrinology assessment |
| Hypothalamic Obesity | rare | Rapid weight gain after hypothalamic tumour, cranial irradiation, surgery, or head trauma | Neuroendocrine history and pituitary/hypothalamic imaging when indicated |
Red Flags & Key History
Symptoms
Rapid unexplained weight gain with proximal weakness, bruising, wide striae, or hypokalemia
Symptoms of OSA with driving sleepiness, resistant hypertension, or pulmonary hypertension
Severe early-onset obesity with hyperphagia or developmental features
Depression, suicidality, binge eating, trauma, or eating disorder symptoms
Chest pain, exertional dyspnea, claudication, or heart failure symptoms
Medication changes temporally linked to weight gain
Food insecurity, shift work, poor sleep, chronic pain, and mobility limitation
Signs
BP elevation, acanthosis nigricans, central adiposity, xanthelasma
Cushingoid signs: facial plethora, proximal myopathy, wide purple striae, easy bruising
Goitre, bradycardia, delayed reflexes, dry skin — hypothyroidism
Hirsutism, acne, androgenic alopecia — PCOS
Hepatomegaly, knee/hip OA signs, venous disease, intertrigo
Signs of heart failure or obesity hypoventilation
Approach to Investigation
First-line
Anthropometrics and stagingBMI, waist circumference, weight trajectory, and obesity-related complication staging; use BMI as screening rather than moral judgement
Cardiometabolic labsA1c or fasting glucose, lipid profile, ALT/AST, creatinine/eGFR, urine ACR if diabetes/hypertension
Blood pressure and cardiovascular risk assessmentIdentify hypertension and global cardiovascular risk
Medication, sleep, mental health, and social historyIdentify iatrogenic weight gain, OSA, depression, binge eating, food insecurity, and barriers to care
Second-line
TSHScreen when symptoms/signs suggest hypothyroidism or as part of reasonable weight-gain workup
Cushing screenOnly if discriminating features are present; avoid low-yield testing for simple obesity alone
Sleep studyIf STOP-Bang or clinical features suggest obstructive sleep apnea
PCOS/metabolic reproductive testsPregnancy test, androgens, prolactin, TSH, A1c/lipids according to menstrual and hyperandrogenism presentation
Specialist
Dietitian, psychologist, exercise professional, bariatric programmeInterprofessional care for sustained behaviour, nutrition, mental health, and mobility support
Obesity medicine/endocrinology or bariatric surgery referralBMI/complication thresholds, severe disease, complex endocrine causes, pharmacotherapy failure, or surgery consideration
Management Principles
Obesity Canada Adult Clinical Practice Guideline and 2025 pharmacotherapy update1
Stigma-aware assessment
- Ask permission to discuss weight and use person-first language
- Focus on health outcomes, function, complications, and patient goals rather than appearance
- Assess root drivers: medications, sleep, pain, mental health, trauma, food access, culture, finances, and environment
2
Lifestyle and behavioural care
- Nutrition pattern tailored to preferences, affordability, culture, and comorbidities
- Physical activity and resistance training scaled to mobility and osteoarthritis; reduce sedentary time
- Behavioural strategies: self-monitoring, relapse planning, sleep optimisation, and psychological treatment when binge eating or mood disorder present
3
Pharmacotherapy and procedures
- Consider Health Canada-approved anti-obesity medications when lifestyle foundation alone is insufficient and indications are met: semaglutide 2.4 mg weekly, liraglutide 3 mg daily, naltrexone/bupropion, or orlistat according to contraindications and availability
- Treat diabetes, hypertension, dyslipidemia, MASLD, and OSA concurrently
- Consider bariatric surgery referral for severe obesity with complications or when guideline criteria are met
Complications & Pitfalls
- Using BMI alone: BMI does not capture complications, fat distribution, ethnicity, function, or lived experience
- Stigmatising counselling: Shame-based advice worsens engagement and outcomes
- Missing secondary causes: Cushing syndrome, hypothyroidism, medications, PCOS, OSA, and genetic causes have specific clues
- Ignoring mental health: Binge eating disorder, depression, trauma, ADHD, and sleep deprivation can drive weight and require specific care
- Stopping pharmacotherapy as a short course: Obesity is chronic and weight regain is common when effective treatment is withdrawn
MCCQE1 Exam Tips
- 1Ask permission to discuss weight — this is a classic CanMEDS communicator move
- 2Obesity management is complications-first, not BMI-only
- 3Cushing discriminators are proximal weakness, bruising, and wide purple striae; simple obesity does not require routine cortisol screening
- 4Medication-induced weight gain is common and highly testable
- 5Metabolic syndrome means cardiovascular risk reduction: BP, lipids, glucose, smoking, activity, and sleep apnea
- 6Canadian pharmacotherapy options include semaglutide, liraglutide, naltrexone/bupropion, and orlistat, selected by contraindications and goals
- 7Bariatric surgery is not cosmetic; it is metabolic risk treatment for selected patients
Put your reading into practice
Topic-specific question practice is not linked for this article yet.
Choose MCCQE Part I questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose MCCQE Part I practiceAfter your session, return to this section to revisit the reading and choose your next review.
Verified Sources & References
related resources
Save your place and choose what comes next
Endocrine & Metabolic · Article 37 of 44